![]() |
|
|
Vol. 290, Issue 3, 1107-1115, September 1999
Graduate School of Pharmaceutical Sciences, University of Tokyo,
Hongo, Bunkyo-ku, Tokyo, Japan (S.A., Y.K., H.K., H.S., Y.S.); Tsukuba
Research Institute, Banyu Pharmaceutical Co., Ltd., Okubo, Tsukuba,
Japan (A.H.); and Department of Medicine, Division of Clinical
Pharmacology and Toxicology, University Hospital, Zurich, Switzerland
(B.S., P.M.)
The endothelin antagonist BQ-123, an anionic cyclopentapeptide, is
taken up by rat hepatocytes through active transport systems. Here, we have examined the hepatocellular uptake mechanism for several
BQ-123 derivatives with anionic charges using isolated rat hepatocytes.
BQ-485, a linear peptide, BQ-518, a cyclic peptide, and compound A, a
cyclic peptide with a cationic moiety, were taken up by hepatocytes in
a concentration-dependent manner. The uptake of BQ-485 was most
efficient, whereas compound A showed comparable uptake with BQ-123. The
uptake of these peptides was Na+- and energy-dependent,
suggesting that active transport mechanisms are involved in their
uptake into hepatocytes. BQ-485, BQ-518, and compound A can almost
completely inhibit both the Na+-dependent and -independent
uptake of [3H]BQ-123, with inhibition constants
(Ki) that are comparable to the
Michaelis-Menten constants (Km) for their
Na+-dependent and -independent uptake, respectively.
Inhibition by BQ-485 was competitive, and the uptake of BQ-485 can be
inhibited by BQ-123, with Ki values that are
comparable with the Km values for BQ-123
uptake. The uptake of BQ-123 by COS-7 cells transfected with either
Na+-dependent taurocholate-cotransporting polypeptide
(Ntcp) or Na+-independent basolateral organic
anion-transporting polypeptide (oatp1) was minimal. Thus, these three
peptides share the transporters that also recognize BQ-123 but appear
to differ from Ntcp and oatp1.
This article has been cited by other articles:
![]() |
R. Nakagomi-Hagihara, D. Nakai, K. Kawai, Y. Yoshigae, T. Tokui, T. Abe, and T. Ikeda OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER Drug Metab. Dispos., May 1, 2006; 34(5): 862 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nasu, Y. Kumagai, H. Kogetsu, M. Tsujimoto, H. Ohtani, and Y. Sawada PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR PRALMORELIN HYDROCHLORIDE IN RATS Drug Metab. Dispos., October 1, 2005; 33(10): 1488 - 1494. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Houle, J. Raoul, J.-F. Levesque, K. S. Pang, D. A. Nicoll-Griffith, and J. M. Silva Retention of Transporter Activities in Cryopreserved, Isolated Rat Hepatocytes Drug Metab. Dispos., April 1, 2003; 31(4): 447 - 451. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kouzuki, H. Suzuki, B. Stieger, P. J. Meier, and Y. Sugiyama Characterization of the Transport Properties of Organic Anion Transporting Polypeptide 1 (oatp1) and Na+/Taurocholate Cotransporting Polypeptide (Ntcp): Comparative Studies on the Inhibitory Effect of their Possible Substrates in Hepatocytes and cDNA-Transfected COS-7 Cells J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 505 - 511. [Abstract] [Full Text] |
||||